Register Login

Seres Therapeutics Inc (MCRB)

  • Event
  • June 07, 2022, 11:36 UTC

(90% Positive) SERES THERAPEUTICS, INC. (MCRB) Announces Enrollment Update for capacity Due to Pandemic-Related Challenges, Patient Enrollment Issues, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 4:37 a.m.

    📋 SERES THERAPEUTICS, INC. (MCRB) - Clinical Trial Update

    Filing Date: 2022-06-07

    Accepted: 2022-06-07 07:36:01

    Event Type: Clinical Trial Update

    Event Details:

    Seres Therapeutics Inc (MCRB) Announces Clinical Trial Update Seres Therapeutics Inc (MCRB) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: capacity, data
    • Diseases/Conditions: commercial supply of SER-109, our products
    • Collaboration: FDA Approval
      • targeting antimicrobial-resistant infections in medically compromised groups (e.g., cancer neutropenia, solid organ transplant) SER-109 Recurrent C. difficile – ECOSPOR III and ECOSPOR IV studies completed; BLA filing initiated 1,2 3 Oncology Research ongoing to determine future ulcerative colitis development plans 1 1 Substantial Recurrent C. difficile Infection Market Opportunity Infectious disease caused by toxin-producing bacteria, resulting in diarrhea, abdominal pain, fever and nausea Leading cause of hospital-acquired infection in the U.S. ~453K cases of primary CDI within the U.S. each year ~170K episodes per year (100K episodes of first recurrence; ~70K episodes of 2+ recurrences) Estimated ~$4.8B in healthcare burden each year Each rCDI patient results in ~$34,000 in direct healthcare expenses per year; substantial additional indirect costs Sources: Desai et al., Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach, BMC Infectious Diseases (2016
      • anticipated indication of SER-109; the potential impact of Infection Protection microbiome therapeutics; our development opportunities and plans; the ultimate safety and efficacy data for our products; the potential of microbiome therapeutics to treat and prevent disease; and other statements which are not historical fact. Such statements are subject to important factors, risks and uncertainties, such as those discussed under the caption "Risk Factors" in the Company’s Quarterly Report on Form 10-Q filed on May 4, 2022

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Seres Therapeutics Inc
    • CIK: 0001609809
    • Ticker Symbol: MCRB
    • Period End Date: 2022-06-07
    • Document Type: 8-K

Search

News categories